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BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)–AKT pathway is activated in many cancers. Mutational hotspots in AKT1 and
in the regulatory and catalytic subunits of PI3K have been detected in multiple tumour types. In AKT1, the E17K substitution leads to a
PI3K-independent activation of AKT1.
METHODS: A mutational profiling of AKT1 and of the mutational hotspots in PIK3CA and PIK3R1 was carried out in samples from
primary and recurrent prostate tumours.
RESULTS: We show that, in prostate cancer, AKT1(E17K) had a prevalence of 1.4%. The mutation seemed to be associated with a
favourable clinical course but it was not associated with a specific tumour growth pattern. Activating mutations in PIK3CA or PIK3R1
were not found in prostate cancer.
CONCLUSION: The E17K substitution in AKT1 is rare in prostate cancer. It seems associated with a favourable clinical outcome but not
with a specific histology of the tumour.
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The phosphatidylinositol 3-kinase (PI3K)–v-akt murine thymoma
viral oncogene homologue (AKT) signalling pathway is involved in
cellular processes such as cell growth, proliferation, apoptosis,
and cytoskeletal rearrangement. PI3K functions by catalysing
the production of phosphorylated phosphoinositides (PtdIns). The
PI3K phosphorylates PtdIns(4,5)P2 (PIP2) into PtdIns(3,4,5)P3
(PIP3), which binds to the pleckstrin homology domain of the
downstream target, v-akt murine thymoma viral oncogene
homologue 1 (AKT1). This results in a recruitment of AKT1
to the plasma membrane in which regulatory amino-acid residues
serine 473 (Ser473) and threonine 308 (Thr308) are phosphory-
lated and activated (Vivanco and Sawyers, 2002).
The tumour-suppressor gene phosphatase and tensin homo-
logue (PTEN) directly antagonises the PI3K–AKT pathway by
converting PIP3 back to PIP2. Absence of PTEN leads to increased
phosphorylation of AKT (Cantley and Neel, 1999), thereby
stimulating PI3K–AKT signalling. PTEN inactivation is frequent
in various cancers, including prostate cancer (Li et al, 1997). It can
occur by deletion (Cairns et al, 1997; Vlietstra et al, 1998; Verhagen
et al, 2006), mutation (Suzuki et al, 1998; Vlietstra et al, 1998;
Verhagen et al, 2006), or by decreased expression (Whang et al,
1998). Prostate-targeted Pten knockout mice develop prostate
hyperplasia, intraepithelial neoplasia, and ultimately invasive
cancer (Wang et al, 2003; Ma et al, 2005).
Activating mutations in AKT1 or PI3K are other mechanisms
that lead to stimulation of the PI3K–AKT pathway. PI3K is
a heterodimer composed of a regulatory subunit (p85a), encoded
by PIK3R1, and a catalytic subunit (p110 a), encoded by PIK3CA.
PIK3CA has frequently been reported as being mutated in
various human cancers (Samuels et al, 2004; Levine et al, 2005).
PIK3R1 mutations are less common, although recently it was
shown that PIK3R1 was mutated in up to 10% of glioblastomas
(Cancer Genome Atlas Research Network, 2008; Parsons et al,
2008). Mutations in either gene lead to a disruption of the
interaction between the regulatory and catalytic subunits, which
enhances enzymatic activity (Huang et al, 2007), thereby activating
the PI3K–AKT pathway. In prostate cancer, however, activating
mutations in PIK3CA or PIK3R1 have not been reported thus far
(Majumder and Sellers, 2005; Ligresti et al, 2009).
Recently, a unique mutation in the pleckstrin homology
domain of AKT1 was identified in breast, ovarian, and colorectal
cancer (Carpten et al, 2007). This G4A mutation results in
a lysine substitution for glutamate at position 17 (E17K) and
leads to a PI3K-independent activation of AKT1. The mutation
was mutually exclusive with respect to mutations in PI3K and
loss of PTEN protein expression. Others confirmed the mutation
in breast and colorectal tumours (Bleeker et al, 2008) and
incidental cases were identified in bladder, endometrial, lung,
and skin cancer (Davies et al, 2008; Do et al, 2008; Malanga et al,
2008; Zilberman et al, 2009; Shoji et al, 2009). An analogous E17K
substitution in AKT3 has also been found in melanomas (Davies
et al, 2008). Previously, we reported on the E17K substitution in
AKT1 in a ductal adenocarcinoma of the prostate in a patient who
had a very long cancer-specific survival (Boormans et al, 2008).
In this study, we analysed the prevalence of AKT1(E17K) in a larger
cohort of prostate cancer patients. We investigated whether the E17K
substitution in AKT1 was associated with a specific growth pattern of
prostate cancer and whether it corresponded with clinical outcome.
MATERIALS AND METHODS
AKT1
Genomic DNA was available from 184 freshly frozen clinical
prostate cancer samples. A total of 85 samples were primary
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sprostate tumours obtained by radical prostatectomy, 88 samples
were locally advanced or recurrent tumours obtained by transur-
ethral resection of the prostate, and 11 samples were hormone-
naı ¨ve prostate cancer lymph node metastases obtained by
pelvic lymph node dissection. An additional 30 formalin-fixed,
paraffin-embedded primary prostate tumours were selected,
including 18 ductal adenocarcinomas of the prostate and
12 primary prostate tumours with the following characteristics:
pathological T stage X pT3a, prostate-specific antigen level
X4.0ngml
 1, any Gleason score, and a cancer-specific survival
of 413 years. From the cancerous regions of the paraffin-
embedded samples, 1-mm core biopsy samples were taken
(Beecher Instruments, Silver Spring, MD, USA). In mutated
samples, a core biopsy sample was taken from adjacent benign
prostatic tissue to test whether the mutation was truly somatic.
Genomic DNA was isolated using the Puregene DNA isolation
kit (BIOzym, Landgraaf, the Netherlands), according to the
manufacturer’s instructions.
PCR analysis was carried out to yield a 198-bp genomic fragment
of AKT1 (see Supplementary Table 1 for primer sequences). PCR
products were identified by 2% agarose gel electrophoresis and
ethidium bromide staining. After ExoSapI (USB, Staufen,
Germany) treatment, the PCR fragments were sequenced with the
reverse AKT1 primer. Sequence reaction products were analysed
on the ABI 3700 automated DNA sequencer (Applied Biosystems,
Carslbad, CA, USA). The freshly frozen samples containing the
E17K substitution in AKT1 were also analysed for PTEN mutations
and for mutations in the mutational hotspots of exons 9 and 20 of
PIK3CA (see Supplementary Table 1 for primer sequences of
PIK3CA and PTEN).
PIK3CA and PIK3R1
Mutational analysis of PIK3CA and PIK3R1 was also carried out on
a subset of 63 freshly frozen tissue samples: 61 transurethral
resection of the prostate samples and two lymph node metastases.
The exons known to contain mutational hotspots were sequenced,
that is, exons 9 and 20 for PIK3CA and exons 14 and 15 for PIK3R1
(see Supplementary Table 1 for primer sequences).
RESULTS AND DISCUSSION
The PI3K–AKT signalling pathway is a central factor in various
cellular processes that are involved in carcinogenesis. The E17K
substitution in AKT1 is an important mechanism that leads to a
PI3K-independent activation of AKT1 (Carpten et al, 2007). Rare
E17K substitution in AKT3 has also been described (Davies et al,
2008). In this study, we focussed on the more common
AKT1(E17K) substitution in prostate cancer. Previously, we
identified AKT1(E17K) in a pure ductal adenocarcinoma of the
prostate in a patient who had a long survival (Boormans et al,
2008). Here, we analysed an additional 18 ductal prostate cancer
samples; however, none of these samples contained the E17K
substitution in AKT1. Therefore, we concluded that an association
between AKT1(E17K) and a specific ductal growth pattern of
prostate cancer is unlikely. This is in contrast to AKT1(E17K) in
breast and lung cancer. In breast cancer, the mutation was unique
for lobular and ductal histotypes (Bleeker et al, 2008), whereas in
lung tumours AKT1(E17K) was only seen in squamous cell
carcinomas (Bleeker et al, 2008; Do et al, 2008; Malanga et al,
2008).
Next, we randomly extended our search for AKT1(E17K) in 184
freshly frozen clinical prostate cancer samples. One extra patient
harbouring the mutation was identified. The sample was a primary
prostate tumour obtained by radical prostatectomy. The tumour
was a moderately differentiated adenocarcinoma (Gleason score
3þ3¼6) with bladder neck involvement (pathological T stage:
pT4a) and positive surgical margins. Moreover, occult pelvic
lymph node metastases were present at the time of radical
prostatectomy. Despite these prognostic unfavourable character-
istics, the patient is still alive at the end of follow-up (survival B17
years). These findings were in agreement with the clinical course of
the patient we described in our previous report (Boormans et al,
2008). That patient was diagnosed with a poorly differentiated
adenocarcinoma (Gleason score 4þ4¼8), but he also had a long
survival (418 years) and he did not die from prostate cancer (see
Table 1a for the clinical and histopathological characteristics of the
patients).
To investigate whether AKT1(E17K) in prostate cancer was
associated with a favourable clinical outcome, as suggested by the
first two patients harbouring the AKT1 mutation, we selected an
additional 12 paraffin-embedded primary prostate tumours. All
patients had unfavourable clinicopathological characteristics;
nevertheless, they had a survival of 413 years (see Materials
and Methods section for selection criteria). In these additional
12 prostate tumours, we identified one extra patient having the
E17K substitution in AKT1. Pathology showed a moderately
differentiated adenocarcinoma (Gleason score 3þ3¼6) with
extracapsular extension (pathological T stage: pT3a) and positive
surgical margins. Almost 18 years after the radical prostatectomy,
the patient died from causes other than prostate cancer.
In a recent series from our institution on patients with clinical
T3 prostate tumours who were treated by radical prostatectomy
and pelvic lymphadenectomy, cancer-specific and overall survival
Table 1a Clinical and histopathological characteristics of three prostate cancer patients harbouring the E17K substitution in AKT1
Patient
Age at diagnosis
(years)
Initial PSA
(ngml
 1)
Primary
treatment
Secondary
treatment
Tertiary
treatment cT-stage pT-stage
Gleason
score
I 74 8.8 WaWa TURP TURP+ET cT2b NA 4+4¼8
II 72 13.0 RP and PLND None None cT2b pT4a 3+3¼6
III 62 5.6 RP and PLND None None cT3x pT3a 3+3¼6
Patient Surgical margins N+ Tissue Histotype Death OS (years) PCa death CSS (years)
I NA NA TURP freshly frozen Ductal adenocarcinoma Yes 18.4 No X18.4
II Positive Yes RP freshly frozen Acinar adenocarcinoma No X17.0 No X17
III Positive No RP PEFF Acinar Adenocarcinoma Yes 16.8 No X16.8
Abbreviations: CSS¼cancer-specific survival; cT-stage¼clinical T stage; ET¼endocrine therapy; NA¼not applicable; OS¼overall survival; PCa death¼prostate cancer death;
PLND¼pelvic lymph node dissection; PEFF¼paraffin-embedded, formalin fixed; PSA¼prostate-specific antigen; pT-stage¼pathological T stage; RP¼radical prostatectomy;
TURP¼transurethral resection of the prostate; WaWa¼watchful waiting.
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In a recent review, it was hypothesised that the presence of
AKT1(E17K) is associated with a less-aggressive form of cancer
(Brugge et al, 2007). The findings of our present series could be in
agreement with such a hypothesis: all three patients harbouring the
E17K substitution in AKT1 had a very long survival despite
aggressive clinicopathological characteristics. Obviously, the find-
ings of this study do not prove an association with better outcome
because of the low prevalence of AKT1(E17K) in prostate cancer.
The mutational profiling of the mutational hotspots of PIK3CA
and PIK3R1 in a subset of 63 prostate cancer patients did not
reveal any mutated sample, which is consistent with earlier
findings (Ligresti et al, 2009).
In conclusion, we have identified three patients harbouring
E17K substitution in AKT1 in prostate cancer, rendering the
reported frequency for AKT1(E17K) in prostate cancer at 1.4% (3
out of 214 patients examined). The mutation showed to be truly
somatic, as the sequence of AKT1 derived from benign prostatic
tissue of patients carrying the mutation was of wild type (data not
shown). AKT1(E17K) seemed to be associated with a favourable
clinical course, but no correlation with a ductal growth pattern of
prostate cancer was found. Furthermore, the E17K substitution in
AKT1 was mutually exclusive with respect to mutations in PTEN
and PIK3CA, as in the freshly frozen samples, mutational profiling
of all nine PTEN exons and of the mutational hotspots of PIK3CA
(exons 9 and 20) showed no mutations (Table 1b). The possibility
of loss of PTEN function by loss of expression was not assessed in
this study.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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